Opinion|Videos|June 11, 2024
Alternative Treatments for eBC and mBC
Key opinion leaders (KOLs) discuss the use of CDK4/6 inhibitors in early breast cancer, specifically in patients who have undergone chemotherapy and surgery. They highlight the key factors that help determine which patients are most likely to benefit from receiving these medications.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- Which phase of treatment is abemaciclib appropriate in?
- What are the patient characteristics that must be present in order to utilize abemaciclib?
- Do these criteria influence your treatment decisions in patients with early breast cancer?
- What is the study design and methods of the NATALEE trial and what have the results demonstrated so far?
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Baxdrostat as First-in-Class Aldosterone Synthase Inhibitor for Hypertension
2
FDA Approves Immgolis and Immgolis Intri as First Biosimilars to Golimumab Reference Products for RA and UC
3
Insulin Deprescribing Utilizing Continuous Glucose Monitoring With Low-Dose Tirzepatide
4
Why Patients Stop Using Their CGMs—and How Pharmacists Can Help
5